---
layout: post
title: "Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction; Draft Guidance for Industry; Availability"
date: 2026-02-04 21:49:34 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-00237
original_published: 2025-01-08 00:00:00 +0000
significance: 8.00
---

# Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction; Draft Guidance for Industry; Availability

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** January 08, 2025 00:00 UTC
**Document Number:** 2025-00237

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction." This draft guidance provides recommendations to industry regarding the development of drugs and biological products regulated within the Center for Drug Evaluation and Research intended for reduction and long-term maintenance of body weight in patients with obesity or overweight. This draft guidance revises and replaces the draft guidance for industry "Developing Products for Weight Management" issued in February 2007.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/01/08/2025-00237/obesity-and-overweight-developing-drugs-and-biological-products-for-weight-reduction-draft-guidance)
- API: https://www.federalregister.gov/api/v1/documents/2025-00237

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
